Menu
Search
|

Menu

Close
X

Neuralstem Inc CUR.OQ (NASDAQ Stock Exchange Capital Market)

0.51 USD
-- (--)
As of Nov 14
chart
Previous Close 0.51
Open --
Volume --
3m Avg Volume 30,607
Today’s High --
Today’s Low --
52 Week High 3.09
52 Week Low 0.48
Shares Outstanding (mil) 18.16
Market Capitalization (mil) 9.27
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.183
FY17
-1.299
FY16
-2.576
FY15
-2.988
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.53
Price to Sales (TTM)
vs sector
18.17
22.95
Price to Book (MRQ)
vs sector
1.25
4.15
Price to Cash Flow (TTM)
vs sector
--
20.94
Total Debt to Equity (MRQ)
vs sector
0.00
15.47
LT Debt to Equity (MRQ)
vs sector
0.00
11.13
Return on Investment (TTM)
vs sector
-64.06
13.00
Return on Equity (TTM)
vs sector
-89.88
14.69

EXECUTIVE LEADERSHIP

William Oldaker
Chairman of the Board, Since 2018
Salary: --
Bonus: --
Jim Scully
Interim Chief Financial Officer, Principal Accounting Officer, Since 2018
Salary: --
Bonus: --
David Recker
Chief Medical Officer, Since 2017
Salary: --
Bonus: --
Xi Chen
Director, Since 2017
Salary: --
Bonus: --
Cristina Csimma
Director, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

20271 Goldenrod Ln Ste 2024
GERMANTOWN   MD   20876-4064

Phone: +1301.3664841

Neuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform. The Company's technology allows the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the treatment of central nervous system diseases and conditions. The Company is developing NSI-189 for the treatment of major depressive disorder (MDD) and other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy. The Company's NSI-566 is indicated for amyotrophic lateral sclerosis (ALS), chronic spinal cord injury and motor deficits due to ischemic stroke.

SPONSORED STORIES